Last reviewed · How we verify
SUGEMALIMAB
Sugemalimab is a marketed drug that modulates the immune response by binding to a specific target on cells. The key composition patent for sugemalimab is set to expire in 2028, providing a clear timeline for potential generic competition. Without specific revenue or trial results, the primary risk remains the competitive landscape, which could impact market share and profitability post-patent expiry.
At a glance
| Generic name | SUGEMALIMAB |
|---|---|
| Modality | Monoclonal antibody |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
| First approval | 2024 |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy of NK510 to Treat NSCLC (EARLY_PHASE1)
- Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma (PHASE3)
- Real-world First-line Sugemalimab-Chemotherapy in Advanced NSCLC (NA)
- Immunodynamics-Guided Optimization of Individualized Immunochemotherapy in Advanced Driver-Negative NSCLC: A Randomized Trial (PHASE1,PHASE2)
- Neoadjuvant Sugemalimab + Chemotherapy Followed by Adjuvant Sugemalimab for Patients With Resectable Stage II-IIIA Non-small-cell Lung Cancer Patients (PHASE2)
- Efficacy and Safety of Chemoimmunotherapy and Carbon Ion Radiotherapy in Unresectable Locally Advanced Non-small Cell Lung Cancer
- A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC (PHASE3)
- Prediction of Response to PD-L1 Inhibitor After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer Using Multi-omics-based Liquid Biopsy
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SUGEMALIMAB CI brief — competitive landscape report
- SUGEMALIMAB updates RSS · CI watch RSS